Literature DB >> 18574133

Whole-brain atrophy rate and cognitive decline: longitudinal MR study of memory clinic patients.

Jasper D Sluimer1, Wiesje M van der Flier, Giorgos B Karas, Nick C Fox, Philip Scheltens, Frederik Barkhof, Hugo Vrenken.   

Abstract

PURPOSE: To prospectively determine whole-brain atrophy rate in mild cognitive impairment (MCI) and Alzheimer disease (AD) and its association with cognitive decline, and investigate the risk of progression to dementia in initially nondemented patients given baseline brain volume and whole-brain atrophy rate.
MATERIALS AND METHODS: This study was IRB approved; written informed consent was obtained; and included 65 AD patients (38 women, 27 men; age, 52-81 years), 45 MCI patients (22 women, 23 men; age, 56-80 years), 27 patients with subjective complaints (12 women, 15 men; age, 50-87 years), and 10 healthy controls (six women, four men; age, 53-80 years). Two magnetic resonance (MR) images were acquired at average interval of 1.8 years +/- 0.7 (standard deviation). Baseline brain volume and whole-brain atrophy rates were measured on three-dimensional T1-weighted MR images (1.0 T; single slab, 168 sections; matrix size, 256 x 256; field of view, 250 mm; voxel size, 1 x 1 x 1.5 mm; repetition time msec/echo time msec/inversion time msec, 15/7/300; and flip angle, 15 degrees ). Associations were assessed by using partial-correlations. Cox proportional hazards models were used to estimate risk of developing dementia.
RESULTS: Baseline brain volume was lowest in AD but did not differ significantly between MCI, subjective complaints, and control groups (P > .38). Whole-brain atrophy rates were higher in AD (-1.9% per year +/- 0.9) than MCI (-1.2% per year +/- 0.9, P = .003) patients, who had higher whole-brain atrophy rates than patients with subjective complaints (-0.7% per year +/- 0.7, P = .03) and controls (-0.5% per year +/- 0.5, P = .05). Whole-brain atrophy rate correlated with annualized Mini-Mental State Examination (MMSE) change (r = 0.48, P < .001), while baseline volume did not (r = 0.11, P = .22). Cox models showed that-after correction for age, sex, and baseline MMSE-a higher whole-brain atrophy rate was associated with an increased risk of progression to dementia (highest vs lowest tertile [hazard ratio, 3.6; 95% confidence interval: 1.2, 11.4]).
CONCLUSION: Whole-brain atrophy rate was strongly associated with cognitive decline. In nondemented participants, a high whole-brain atrophy rate was associated with an increased risk of progression to dementia.

Entities:  

Mesh:

Year:  2008        PMID: 18574133     DOI: 10.1148/radiol.2482070938

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  61 in total

1.  Localized hippocampus measures are associated with Alzheimer pathology and cognition independent of total hippocampal volume.

Authors:  Owen Carmichael; Jing Xie; Evan Fletcher; Baljeet Singh; Charles DeCarli
Journal:  Neurobiol Aging       Date:  2011-12-14       Impact factor: 4.673

2.  Temporal evolution of biomarkers and cognitive markers in the asymptomatic, MCI, and dementia stage of Alzheimer's disease.

Authors:  Daniela Bertens; Dirk L Knol; Philip Scheltens; Pieter Jelle Visser
Journal:  Alzheimers Dement       Date:  2014-08-20       Impact factor: 21.566

3.  Knowing the natural course of biomarkers in AD: longitudinal MRI, CSF and PET data.

Authors:  W M Van Der Flier; P Scheltens
Journal:  J Nutr Health Aging       Date:  2009-04       Impact factor: 4.075

4.  Relationship between regional atrophy rates and cognitive decline in mild cognitive impairment.

Authors:  Carrie R McDonald; Lusineh Gharapetian; Linda K McEvoy; Christine Fennema-Notestine; Donald J Hagler; Dominic Holland; Anders M Dale
Journal:  Neurobiol Aging       Date:  2010-05-14       Impact factor: 4.673

5.  The bidirectional association between reduced cerebral blood flow and brain atrophy in the general population.

Authors:  Hazel I Zonneveld; Elizabeth A Loehrer; Albert Hofman; Wiro J Niessen; Aad van der Lugt; Gabriel P Krestin; M Arfan Ikram; Meike W Vernooij
Journal:  J Cereb Blood Flow Metab       Date:  2015-07-08       Impact factor: 6.200

Review 6.  The clinical use of structural MRI in Alzheimer disease.

Authors:  Giovanni B Frisoni; Nick C Fox; Clifford R Jack; Philip Scheltens; Paul M Thompson
Journal:  Nat Rev Neurol       Date:  2010-02       Impact factor: 42.937

7.  Cerebrospinal fluid biomarkers and cerebral atrophy in distinct clinical variants of probable Alzheimer's disease.

Authors:  Rik Ossenkoppele; Niklas Mattsson; Charlotte E Teunissen; Frederik Barkhof; Yolande Pijnenburg; Philip Scheltens; Wiesje M van der Flier; Gil D Rabinovici
Journal:  Neurobiol Aging       Date:  2015-04-25       Impact factor: 4.673

8.  Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial.

Authors:  A David Smith; Stephen M Smith; Celeste A de Jager; Philippa Whitbread; Carole Johnston; Grzegorz Agacinski; Abderrahim Oulhaj; Kevin M Bradley; Robin Jacoby; Helga Refsum
Journal:  PLoS One       Date:  2010-09-08       Impact factor: 3.240

9.  Hippocampal atrophy rates in Alzheimer disease: added value over whole brain volume measures.

Authors:  W J P Henneman; J D Sluimer; J Barnes; W M van der Flier; I C Sluimer; N C Fox; P Scheltens; H Vrenken; F Barkhof
Journal:  Neurology       Date:  2009-03-17       Impact factor: 9.910

Review 10.  Advances in longitudinal studies of amnestic mild cognitive impairment and Alzheimer's disease based on multi-modal MRI techniques.

Authors:  Zhongjie Hu; Liyong Wu; Jianping Jia; Ying Han
Journal:  Neurosci Bull       Date:  2014-02-27       Impact factor: 5.203

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.